Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04446507 · ClinicalTrials.gov registry record · Phase 1
A Pharmacokinetic Study of Saroglitazar Magnesium in Subjects with Severe Renal Impairment and Normal Renal Function
A Phase 1 study, sponsored by Zydus Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT04446507 is a Phase 1 study that has completed, run by Zydus Therapeutics. The registered enrollment target is 32 participants.
The verdict
NCT04446507, a Phase 1 study, has completed, sponsored by Zydus Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
This will be a Phase 1, Open-label Study of Participants with Normal Renal Function and Participants with Sever Renal Impairment.
Interventions
- DRUG Saroglitazar magnesium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2020-07-27 |
| Est. Completion | 2024-05-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04446507
The ClinicalTrials.gov registry entry for NCT04446507 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Zydus Therapeutics, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Saroglitazar magnesium is the first listed.
NCT04446507 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04446507 about?
NCT04446507 is a clinical study titled "A Pharmacokinetic Study of Saroglitazar Magnesium in Subjects with Severe Renal Impairment and Normal Renal Function". This will be a Phase 1, Open-label Study of Participants with Normal Renal Function and Participants with Sever Renal Impairment.
What is the current status of trial NCT04446507?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2020-07-27. Estimated completion is 2024-05-28.
What interventions are being tested in trial NCT04446507?
The interventions under investigation include: Saroglitazar magnesium (DRUG).
Who is sponsoring clinical trial NCT04446507?
This trial is sponsored by Zydus Therapeutics, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.